Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant <i>Erwinia</i> in pediatrics and adolescents/young adults with acute lymphoblastic leukemia

AIMS: in pediatric and adolescent/young adult (AYA) patients aged <40 years with acute lymphoblastic leukemia (ALL), overall and by use of therapeutic drug monitoring (TDM). MATERIALS AND METHODS: . Outcomes were compared between patients who received TDM and those who did not. RESULTS: < 0.0003), respectively. LIMITATIONS: Caution is required in the interpretation of the results of this retrospective study as claims data are not designed specifically for research purposes. CONCLUSIONS: is associated with higher healthcare costs. Consideration should be given to TDM, which may mitigate unnecessary switches of asparaginase.